title: Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.
abstract: We measured neutralizing antibodies (NABs) and the in vivo biologic response to interferon-beta on neopterin and beta(2)-microglobulin blood levels. All NAB-negative patients had an in vivo biologic response (full or partial), whereas all high-level positive patients had no response. High-level NAB patients had more MRI activity than NAB-negative patients (p = 0.031). Patients with a full response had less MRI activity than patients without biologic response (p = 0.032).
authors.affiliation: Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. pss@rh.dk
authors.forename: P Soelberg
authors.initials: PS
authors.lastname: Sorensen
authors.forename: T
authors.initials: T
authors.lastname: Tscherning
authors.forename: H K
authors.initials: HK
authors.lastname: Mathiesen
authors.forename: A R
authors.initials: AR
authors.lastname: Langkilde
authors.forename: C
authors.initials: C
authors.lastname: Ross
authors.forename: M
authors.initials: M
authors.lastname: Ravnborg
authors.forename: K
authors.initials: K
authors.lastname: Bendtzen
mesh_terms: D000328:Adult; D000906:Antibodies / Q000097:blood*; D001921:Brain / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D018450:Disease Progression; D004351:Drug Resistance / Q000276:immunology*; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000037:antagonists & inhibitors* / Q000276:immunology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D019798:Neopterin / Q000097:blood / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D019798:Neopterin; D016899:Interferon-beta